Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder

Current Medical Research and Opinion

Volumn 23, Issue 2, 2007, Pages 251-258

  Armstrong, Edward P ^a   Skrepnek, Grant H ^a   Erder, M Haim ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Cost utility; Escitalopram; Major depressive disorder; Sertraline

Indexed keywords

ESCITALOPRAM; SERTRALINE;

ARTICLE; CONTROLLED STUDY; COST UTILITY ANALYSIS; DIARRHEA; DRUG COST; DRUG DOSE TITRATION; EJACULATION DISORDER; HEADACHE; HEALTH CARE COST; HUMAN; INSOMNIA; MAJOR DEPRESSION; MONTE CARLO METHOD; NAUSEA; QUALITY ADJUSTED LIFE YEAR; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS; CITALOPRAM; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DEPRESSIVE DISORDER; DIARRHEA; DRUG COSTS; FEMALE; HEADACHE; HUMANS; IMPOTENCE; MALE; MONTE CARLO METHOD; NAUSEA; OFFICE VISITS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 33847414682     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X159498     Document Type: Article

References (29)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
2. Davidson JRT, Meltzer-Brody SE. The underrecognition and undertreatment of depression: what is the breadth and depth of the problem? J Clin Psychiatry 1999;60(Suppl):4-9
3. Hirschfeld R, Keller M, Panico S, et al. The national depressive and manic-depressive association consensus statement on the undertreatment of depression. JAMA 1997;227:333-40
4. Saklad SR. Pharmacoeconomic issues in the treatment of depression. Pharmacotherapy 1995;15:76-83
5. Panzarino PJ Jr, Nash DB. Cost-effective treatment of depression with selective serotonin reuptake inhibitors. Am J Manag Care 2001;7:173-84
6. Leon AC, Solomon DA, Mueller TI, et al. A 20-year longitudinal observational study of somatic antidepressant treatment effectiveness. Am J Psychiatry 2003;160:727-33
7. Meyers BS, Sirey JA, Bruce M, et al. Predictors of early recovery from major depression among persons admitted to community-based clinics: an observational study. Arch Gen Psychiatry 2002;59:729-35
8. Cohen LJ. Pharmacoeconomic issues in the treatment of depression. Formulary 1995;30 (Suppl):20-5
9. Fabre LF, Abuzzahab FS, Amin M, et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995;38:592-602
10. Lexapro® prescribing information. Forest Pharmaceuticals, Inc. Revised February 2005
11. Zoloft® prescribing information. Pfizer, Inc. Revised February 2005
12. Dunner DL, Dunbar GC. Optimal dose regimen for paroxetine. J Clin Psychiatry 1992;53(Suppl):21-6
13. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001;50:345-50
14. Sanchez C, Bergqvist PB, Brennum LT, et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 2003;67:353-62
15. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-75
16. Croghan TW. The controversy of increased spending for antidepressants. Health Affairs 2001;20:129-35
17. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
18. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
19. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: Superintendent of Documents, US Government Printing Office, US Department of Health, Education, and Welfare Publication No. 76-338; 1976
20. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-5
21. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological Measurement 1977;1:385-401
22. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-6
23. National Committee for Quality Assurance Programs: The health plan employer data and information set (HEDIS®). Internet: www.ncqa.org/Programs/ HEDIS/ accessed July 29, 2005
24. Ventura D, Armstrong EP, Skrepnek GH, et al. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr Med Res Opinion 2007;23:245-50
25. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002;63:331-6
26. Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004;18:911-32
27. McLaughlin TP, Eaddy MT, Grudzinski AN. A claims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: impact on depression-related treatment charges. Clin Ther 2004;26:115-24
28. Physician fee schedule, Center for Medicare & Medicaid Services. Internet: www.cms.hhs.gov/physicians/pfs/default.asp accessed: January 3, 2005
29. drugstore.com Online Pharmacy. Internet: www.drugstore.com accessed January 3, 2005